Every material Form 8-K Tarsus Pharmaceuticals, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tarsus Pharmaceuticals reported third-quarter 2026 results in a press release furnished as Exhibit 99.1 to this 8-K. XDEMVY net product sales rose approximately 64% year over year to $194.6 million, but a $632.2 million acquired in-process R&D expense tied to the iRenix and Alkeus acquisitions pushed the net loss to $668.3 million, or $(14.40) per share, compared with $12.6 million, or $(0.30) per share, a year earlier.
Third-quarter product sales, net were $194.6 million, compared with $118.7 million in the same period of 2025.
Acquired IPR&D expense of $632.2 million included $551.2 million for Alkeus and $81.0 million for iRenix.
Net loss was $668.3 million, or $(14.40) per share, versus $12.6 million, or $(0.30) per share, a year earlier.
Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, paying $270 million in cash and issuing 2,908,692 shares at closing. Alkeus shareholders may also receive up to $350 million in milestone payments tied to regulatory approval and first U.S. sales, plus revenue-sharing payments on future gildeuretinol sales. The filing does not provide financial results for Alkeus, so its effect on Tarsus's financials is not yet quantified.
Acquisition closed September 4, 2026, with Alkeus becoming a wholly-owned subsidiary of Tarsus
Up-front consideration: $270,000,000 in cash, subject to adjustments, plus 2,908,692 shares of common stock
Milestones up to $350 million: $250 million on U.S. regulatory approval of an Alkeus product, and $100 million in cash on first U.S. sale
Financial statements and pro forma information will be filed by amendment within 71 calendar days
Tarsus Pharmaceuticals reported second-quarter 2026 XDEMVY net product sales of $173.9 million, up from $102.7 million a year earlier, and raised its full-year 2026 XDEMVY sales guidance to $685-705 million. The company also reported a smaller net loss, and it has a pending acquisition of Alkeus Pharmaceuticals along with a $125 million private placement.
Q2 2026 net product sales were $173.9 million, compared with $102.7 million in Q2 2025.
Full-year 2026 XDEMVY net product sales guidance raised to $685-705 million.
Q2 2026 net loss was $18.6 million, or $(0.43) per share, compared with $20.3 million, or $(0.48) per share, a year earlier.
Pending acquisition of Alkeus Pharmaceuticals; $125 million private placement priced. Cash and marketable securities were $449.7 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tarsus Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →